With the new financing, Precipoint plans to expand internationally and enter the US market. Furthermore, the Freising drive further technological development.
Precipoint develops digitization solutions in the field of microscopy and, according to its own statements, is represented with its devices in many laboratories worldwide. Applications include medicine, research, and teaching. The company's products allow samples to be viewed without expensive and time-consuming pretreatment.
Precipoint: “The conditions have been created to scale the company quickly.”
This year, Precipoint presented the iO:M8 ROSE solution. This enables digital examinations during ongoing cancer surgeries. Pathologists can thus determine during the procedure whether sufficient material has been removed from the patient's body and whether the edges of the surgical site are free of cancer cells. Previously, such examinations were performed on-site using conventional light microscopes. Precipoint's digital solution is intended to improve patient care and enable significant cost savings.
Stefan Jahn, Senior Investment Manager at Bm|t says:
"Since our seed investment in 2019, the team around the two co-founders and managing directors Nicolas Weiß and Dominik Gerber has made tremendous progress. Renowned distribution partners have been acquired, new products have been quickly developed, and successfully launched. At the same time, the conditions have been laid to rapidly scale the company. We firmly believe that Precipoint, as an ISO 13485-certified medical technology company, can successfully position its product portfolio on the European and American markets."
